AKT1 and acute myeloid leukemia: The continuous activation of PI3K/AKT conferred by ATRA dramatically gave growth advantages to AML cells, which might be responsible for the failure of ATRA monotherapy in AML patients, as shown in our results that ATRA alone failed to induce obvious cell apoptosis in AML.